Dermatologic adverse events associated with gamma secretase inhibitor nirogacestat: A retrospective multicenter cohort study - 19/11/25
Doi : 10.1016/j.jaad.2025.08.002
Grant J. Riew, AB a, b, Lauren M. Guggina, MD a, b, c, Federico Repetto, MD a, d, Christine G. Lian, MD a, d, Alexandra P. Charrow, MD, MBE a, b, Nicole R. LeBoeuf, MD, MPH a, b, c, Connie R. Shi, MD a, b, c, ⁎ 
a Harvard Medical School, Boston, Massachusetts
b Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts
c Department of Cutaneous Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
d Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts
∗ Correspondence to: Connie R. Shi, MD, Department of Dermatology, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115 Department of Dermatology Brigham and Women's Hospital 75 Francis St Boston MA 02115
Key words : cutaneous toxicities, dermatologic adverse events, desmoid tumor, gamma secretase inhibitor, nirogacestat, skin toxicities
| Funding sources: None. |
|
| Patient consent: The authors attest to obtaining written patient consent for the publication of recognizable patient photographs or other identifiable material, with the understanding that this information may be publicly available. |
|
| IRB approval status: This study was approved by the Mass General Institutional Review Board. |
© 2025
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 93 - N° 6
P. 1555-1557 - décembre 2025 Retour au numéro
Article précédent
- Cutaneous manifestations of tear gas exposure: A systematic review
- Ben Gratz, Nesreen Shahrour, Layan Shahrour, Yoseph Dalia
- Screening strategies used by academic dermatology programs to allocate away rotation opportunities for visiting medical students
- Dana H. Chung, Severine Z. Cao, Grace A. Osborne, Sara L. Fossum, Blair A. Jenkins, Julie E. Mervak
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?